Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.
暂无分享,去创建一个
Wei Zhang | Jeanne Kowalski | Hua-Ling Tsai | Michael A McDevitt | Wei Zhang | J. Herman | M. McDevitt | L. Gondek | J. Maciejewski | Min Guo | J. Kowalski | B. Smith | J. Karp | Y. Ye | S. Gore | H. Carraway | O. Galm | C. Hooker | Hsing-Chen Tsai | James G Herman | Mingzhou Guo | Oliver Galm | Steven D Gore | Craig Hooker | Judith E Karp | B Douglas Smith | Ying Ye | Hetty E Carraway | Xiaofei Wang | Xiaofei Wang | Jaroslaw P Maciejewski | H. Tsai | Lukasz P Gondek | Hsing-Chen Tsai | J. Kowalski
[1] P. Fenaux,et al. The role of lenalidomide in the management of myelodysplasia with del 5q , 2008, British journal of haematology.
[2] Stephan Sauer,et al. Chromatin signatures of pluripotent cell lines , 2006, Nature Cell Biology.
[3] A. List,et al. KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients. , 2001, Leukemia research.
[4] C. Bloomfield,et al. Molecular cytogenetic characterization of the KG‐1 and KG‐1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization , 2003, Genes, chromosomes & cancer.
[5] D. Teng,et al. Localization of SMAD5 and its evaluation as a candidate myeloid tumor suppressor. , 1997, Cancer research.
[6] Megan F. Cole,et al. Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.
[7] Yongning Zhou,et al. α-catenin expression is decreased in patients with gastric carcinoma , 2005 .
[8] P. Nowell,et al. Physical mapping of the minimal region of loss in 5q- chromosome. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Herman,et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. , 2008, Cancer research.
[10] S. Nimer,et al. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Schoch,et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.
[12] S. Nishizuka,et al. Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. , 1996, Cancer research.
[13] Y. Doki,et al. E-Cadherin and α-Catenin Expression in Human Esophageal Cancer , 1994 .
[14] T. Golub,et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.
[15] Kelly M. McGarvey,et al. A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.
[16] D. Oscier,et al. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome , 1993 .
[17] James A. Cuff,et al. A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.
[18] N. Zhao,et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[19] J. Herman,et al. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia , 2005, Annals of Hematology.
[20] N. Satoh,et al. Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. , 1996, Gastroenterology.
[21] M. Greaves,et al. Divergent molecular phenotypes of KG1 and KG1a myeloid cell lines. , 1986 .
[22] T. Haferlach,et al. Discovery of epigenetically silenced genes in acute myeloid leukemias , 2007, Leukemia.
[23] Z. Arbieva,et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. , 2000, Blood.
[24] S. Natsugoe,et al. α‐catenin is a significant prognostic factor than E‐cadherin in esophageal squamous cell carcinoma , 2007 .
[25] J. Herman,et al. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. , 1999, Blood.
[26] John Anastasi,et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. , 2007, Blood.
[27] J. Issa,et al. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. , 2006, Haematologica.
[28] R. Verhaak,et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.
[29] Kelly M. McGarvey,et al. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. , 2006, Cancer research.
[30] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[31] W. Gerald,et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.
[33] P. Mendes-da-Silva,et al. Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma , 2000, Molecular pathology : MP.
[34] B. Quesnel,et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. , 1998, Blood.
[35] W. Hiddemann,et al. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q , 2005, Leukemia.
[36] Michael F Clarke,et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation , 2007, Nature Medicine.
[37] J. Zavadil,et al. Smad5, a tumor suppressor candidate at 5q31.1, is hemizygously lost and not mutated in the retained allele in human leukemia cell line HL60 , 1997, Leukemia.
[38] R. Larson,et al. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. , 1996, Blood.
[39] J. Boultwood,et al. The 5q-syndrome. , 1994, Blood.
[40] A. Kasprzyk,et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. , 2002, Blood.
[41] J. Herman,et al. E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] J. Herman,et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. , 1997, Cancer research.
[43] P. Guldberg,et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patients , 2006, European journal of haematology.
[44] M. Pfeilstöcker,et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. , 2001, Blood.
[45] S. Nimer,et al. The 5q- abnormality. , 1987, Blood.
[46] C. Plass,et al. Alterations of DNA methylation in hematologic malignancies. , 2002, Cancer letters.
[47] D. Oscier,et al. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome. , 1993, Blood.
[48] R. Liang,et al. Hypermethylation of gene promoters in hematological neoplasia , 2002, Hematological oncology.